iPierian snags $3.7M grant from NIH for cell reprogramming
iPierian, a South San Francisco-based company that’s researching the use of cellular reprogramming for drug discovery applications, has been selected by the National Institutes of Health for a $3.7 million grant to continue work on these topics in tandem with Johns Hopkins University.
The two-year “Great Opportunities” grant is actually part of the federal stimulus package to help fuel neurological and stroke-related research. Its work could eventually be used to treat ALS, Parkinson’s and spinal muscular atrophy.
The company is financed by Kleiner Perkins Caufield & Byers, MPM Capital, FinTech Global Capital and Highland Capital Partners. It merged with iZumi Bio in July, generating another $11.5 million in funding.
Next Story: Tioga Energy captures $1M to broker solar power purchase agreements
Previous Story: Power.com lawsuit against Facebook dismissed
About the Author, Camille Ricketts
Camille is the lead writer for GreenBeat. She came to VentureBeat from Google where she worked on its traditional platforms team, particularly in TV. Before that, she was a reporter for the Wall Street Journal in New York and London. Follow her on Twitter at @camillericketts, and follow VentureBeat on Twitter at @venturebeat.